A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4; 11) acute lymphoblastic leukemia

Blood

Volumn 95, Issue 1, 2000, Pages 96-101

  Cimino, Giuseppe ^a   Elia, Loredana ^b   Rapanotti, Maria Cristina ^b   Sprovieri, Teresa ^b   Mancini, Marco ^b   Cuneo, Antonio ^b   Mecucci, Cristina ^b   Fioritoni, Giuseppe ^b   Carotenuto, Mario ^b   Morra, Enrica ^b   Liso, Vincenzo ^b   Annino, Luciana ^b   Saglio, Giuseppe ^b   De Rossi, Giulio ^b   Foà, Robin ^b   Mandelli, Franco ^b  

^a Dipto Biotecnologie Cellulari ed E   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOGENETICS; DISEASE COURSE; FEMALE; HUMAN; INFANT; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 4; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSLOCATION, GENETIC;

EID: 0033961821     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Haluska FG, Tsujimoto Y, Croce CM. Oncogene activation by chromosome translocation in human malignancy Annu Rev Genet. 1987;21:321-345.
2. Greaves MF. Aetiology of acute leukaemia. Lancet. 1997;349:344-349.
3. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278: 1059-1064.
4. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995; 85:1416-1434.
5. Fey MF, Kulozik AE, Hansen-Hagge TE, Tobler A. The polymerase chain reaction: a new tool for the detection of minimal residual disease in haematological malignancies. Eur J Cancer. 1991;27: 89-94.
6. Thompson JD, Brodsky I, Yunis JJ. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood. 1992;79:1629-1635.
7. Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet. 1992;340:1437-1438.
8. Biondi A, Rambaldi A, Rossi V, et al. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood. 1993;82:2943-2947.
9. Janssen JW, Ludwig WD, Borkhardt A, et al. Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood. 1994;84:3842-3853.
10. Cimino G, Elia L, Rivolta A, et al. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/ AF-4 positive-acute lymphoblastic leukaemia. Br J Haematol. 1996;92:659-664.
11. Pui CH, Frankel LS, Carroll AJ, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4; 11)(q21;q23): a collaborative study of 40 cases. Blood. 1991;77:440-447.
12. Schardt C, Ottmann OG, Hoelzer D, Ganser A. Acute lymphoblastic leukemia with the t(4;11) translocation: combined cytogenetic, immunological and molecular genetic analyses. Leukemia. 1992;6:370-374.
13. Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood. 1993;81:2237-2251.
14. Cimino G, Rapanotti MC, Sprovieri T, Elia L. ALL1 gene alterations in acute leukemia: biological and clinical aspects. Haematologica. 1998;83:350-357.
15. Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood. 1993;81:2386-2393.
16. Cimino G, Lo Coco F, Biondi A, et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood. 1993;82: 544-546.
17. Cimino G, Moir DT, Canaani O, et al. Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23),t(9;11)(p21;q23), and t(11; 19)(q23;p13) chromosome translocations. Cancer Res. 1991;51:6712-6714.
18. Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias Proc Natl Acad Sci USA. 1991;88:10,735-10,739.
19. Djabali M, Sellari L, Parry P, Bower M, Young BD, Evans GA. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet. 1992;2:113-118.
20. Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992;71:701-708.
21. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992;71:691-700.
22. Morrissey J, Tkachuk DC, Milatovich A, Francke U, Link M, Cleary ML. A serine/proline-rich protein is fused to HRX in t(4;11) acute leukemias. Blood. 1993;81:1124-1131.
23. Yamamoto K, Seto M, Iida S, et al. A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric mRNAs in leukemia with 11q23 abnormalities. Blood. 1994;83:2912-2921.
24. Uckun FM, Herman-Hatten K, Crotty ML, et al. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood. 1998;92:810-821.
25. Hunger SP, Cleary ML. What significance should we attribute to the detection of MLL fusion transcripts? Blood. 1998;92:709-711.
26. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol. 1976;33:451-458.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
28. Mandelli F, Annino L, Vegna ML, et al. GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia: preliminary results. Leukemia. 1992;6(suppl 2):182-185.
29. Annino L, Ferrari A, Del Poeta G, et al. Myeloid-like induction for adult acute lymphoblastic leukemia (ALL). The GIMEMA ALL0394 pilot study. Paper presented at: XIIIth Meeting of the Therapeutical Society of Hematology: September, 1995; Istanbul, Turkey.
30. Todeschini G, Tecchio C, Meneghini V, et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 1998;12:144-149.
31. Conter V, Arico M, Colella R, et al. Childhood acute lymphoblastic leukemia (ALL): results of the AIEOP 88 protocol [abstract]. Med Pediatr Oncol. 1993;21:557a.
32. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-1738.
33. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-3367.
34. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712-715.
35. Poirel H, Radford-Weiss I, Rack K, et al. Detection of the chromosome 16 CBFβ-MYH11 fusion transcript in myelomonocytic leukemias. Blood. 1995;85:1313-1322.
36. Bloomfield CD, Secker-Walker L, Goldman Al, et al. Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1989;40:171-185.
37. Hagemeijer A, van der Plas DC. Clinical relevance of cytogenetics in acute leukemia. Hamatol Bluttransfus. 1990;33:23-30.
38. Pui CH, Carroll LAJ, Raimondi SC, Shuster JJ, Crist WM, Pullen DJ. Childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): an update. Blood. 1994;83:2384-2385.
39. Secker-Walker LM. General report on the European Union Concerted Action Workshop on 11q23: London, UK, May 1997. Leukemia. 1998; 12:776-778.
40. Schichman SA, Caligiuri MA, Gu Y, et al. ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci U S A. 1994;91:6236-6239.
41. Angioni A, La Starza R, Mecucci C, et al. Interstitial insertion of AF10 into the ALL1 gene in a case of infant acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1998;107:107-110.
42. Preudhomme C, Revillion F, Merlat A, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia. 1999;13:957-964.
43. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997;16:4226-4237.
44. Dördelmann M, Reiter A, Borkhardt A, et al, for the ALL-BFM Group. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94: 1209-1217.
45. Ludwig WD, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92:1898-1909.